期刊文献+

胆固醇抑制剂洛伐他汀对MCF-7细胞增殖分化功能及形态结构的影响 被引量:3

Effects of cholesterol inhibitor-lovastatin on proliferation & differentiation and morphology of MCF-7 cells
暂未订购
导出
摘要 目的 探讨洛伐他汀 (Lovastatin ,LOV)对MCF 7细胞增殖、分化功能及细胞形态、结构的影响。方法 LOV处理细胞 1~ 3d后 ,MTT比色法检测细胞增殖功能 ,流式细胞仪分析细胞周期相分布及细胞凋亡率 ,同时观察细胞形态、结构的改变。结果 LOV可导致细胞形态、结构改变 ;细胞增殖抑制 ,生长阻滞于G0 /G1期 ;同时LOV有诱导该细胞向正常细胞分化的趋势 ,但诱导细胞凋亡的作用不明显。结论 LOV可导致MCF 7细胞形态、功能改变 ,细胞增殖受抑、生长阻滞于G0 /G1期 。 Objective To study the effects of lovastatin (LOV) on proliferation & differentiation and morphology of MCF 7 cells. Methods After treated MCF 7 cells with LOV for 1~3d, the proliferation of MCF 7 cells were examined with MTT test and the distributions of cell cycles with FCM assay. Meanwhile the morphological change was observed.Results LOV could change the morphology and ultra structure of MCF 7 cells significantly, inhibit the proliferation of MCF 7 cells, induce differentiation and arrest MCF 7 cells in the G 0/G 1 phase of cell cycle. However, apoptosis in MCF 7 cells treated with LOV was not obvious.Conclusion It suggests that LOV has the capabilities of inducing cellular morphological changes, inhibiting proliferation and arresting MCF 7 cells in G 0/G 1 phase of cell cycle. Meanwhile it induces the differentiation of MCF 7 cells.
出处 《肿瘤防治研究》 CAS CSCD 2003年第3期210-213,共4页 Cancer Research on Prevention and Treatment
关键词 乳腺癌 洛伐他汀 胆固醇抑制剂 细胞增殖 细胞分化 细胞形态 Lovastatin Human breast cancer cell Cholesterol Differentiation Proliferation
  • 相关文献

参考文献1

二级参考文献2

  • 1Wang I K,Pharmacol Toxicol,2000年,86卷,83页
  • 2Choi J W,J Pharm Exp Ther,1999年,289卷,572页

共引文献9

同被引文献40

  • 1张明,姜达.他汀类药物在抗肿瘤中的研究进展[J].肿瘤防治研究,2004,31(11):714-717. 被引量:6
  • 2邵志敏 张杰 李方明 见:沈镇宙 邵志敏.乳腺癌的预后因素[A].见:沈镇宙,邵志敏.现代乳腺肿瘤学进展[C].上海:上海科学技术文献出版社,2002.4,79--]00.
  • 3傅西林.乳腺肿瘤病理组织学诊断[A].见:李树玲主编.乳腺肿瘤学[C].北京:科学技术文献出版社,2000.57~130.
  • 4:hristophe D,'Marc V,Marie K,et al. Cerivastatin,an inhibitor of HMG CoA reduetase,inhibits the signaling pathways involved in the invasivekess and metastatic properties of highly invasive breast cancer cell lines : Ln in vitro study. Carcinogenesis,2001,22 : 1139-1148.
  • 5Banke A, Sanjay B, Balasz H, et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clinical Cancer Research, 1999,5:2223-2229.
  • 6Wojciech F, Izabeta Y, Ewa Z, et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of Dox0rubicin in three tumor models in mice. Clinical Cancer Research ,2000,6:2044-2052.
  • 7Vega GL, Weiner MF, Lipton AM, et al. Reduction in Levels of 24S- Hydroxycholesterol by Statin treatment in Patiens with Alzhei mer disease. Arch Neurol,60,510-515.
  • 8Youssef S, Stuve D, Patarroyo PJ, et al. The HMG-CoA reductase inhibitor,atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002,420:78 -84.
  • 9Narisawa T, Morotomi M, Fukaura Y, et 81. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of Nmethyl,N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res, 1996,87:988.
  • 10Marco R, Lorenzo A, Paul M, et al. Pharmacological control of the meval- onate pathway:effect on arterial smooth muscle cell proliferation. JPET, 1997,3:1144-1153.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部